Huaren Pharmaceutical Co Ltd (300110) - Total Assets

Latest as of September 2025: CN¥3.40 Billion CNY ≈ $497.06 Million USD

Based on the latest financial reports, Huaren Pharmaceutical Co Ltd (300110) holds total assets worth CN¥3.40 Billion CNY (≈ $497.06 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Huaren Pharmaceutical Co Ltd book value and equity for net asset value and shareholders' equity analysis.

Huaren Pharmaceutical Co Ltd - Total Assets Trend (2007–2024)

This chart illustrates how Huaren Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data.

Huaren Pharmaceutical Co Ltd - Asset Composition Analysis

Current Asset Composition (December 2024)

Huaren Pharmaceutical Co Ltd's total assets of CN¥3.40 Billion consist of 34.6% current assets and 65.4% non-current assets.

Asset Category Amount (CNY) % of Total Assets
Cash & Equivalents CN¥0.00 4.8%
Accounts Receivable CN¥663.15 Million 19.3%
Inventory CN¥318.24 Million 9.3%
Property, Plant & Equipment CN¥0.00 0.0%
Intangible Assets CN¥307.63 Million 9.0%
Goodwill CN¥732.61 Million 21.4%

Asset Composition Trend (2007–2024)

This chart illustrates how Huaren Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Huaren Pharmaceutical Co Ltd.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Huaren Pharmaceutical Co Ltd's current assets represent 34.6% of total assets in 2024, a decrease from 44.9% in 2007.
  • Cash Position: Cash and equivalents constituted 4.8% of total assets in 2024, up from 3.7% in 2007.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 29.0% of total assets, an increase from 4.0% in 2007.
  • Asset Diversification: The largest asset category is goodwill at 21.4% of total assets.

Huaren Pharmaceutical Co Ltd Competitors by Total Assets

Key competitors of Huaren Pharmaceutical Co Ltd based on total assets are shown below.

Company Country Total Assets
Changchun High & New Technology Industries Group Inc
SHE:000661
China CN¥31.46 Billion
Yuhan Corp.
KO:000100
Korea ₩3.05 Trillion
Tasly Pharmaceutical Group Co Ltd
SHG:600535
China CN¥15.34 Billion
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
China CN¥15.32 Billion
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
China CN¥10.96 Billion
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
China CN¥1.54 Billion
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
China CN¥6.74 Billion
Cronos Group Inc
TO:CRON
Canada CA$1.18 Billion

Huaren Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 0.74 1.78 1.51
Quick Ratio 0.58 1.56 1.27
Cash Ratio 0.00 0.00 0.00
Working Capital CN¥-400.29 Million CN¥1.11 Billion CN¥541.69 Million

Huaren Pharmaceutical Co Ltd - Advanced Valuation Insights

This section examines the relationship between Huaren Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 2.79
Latest Market Cap to Assets Ratio 0.16
Asset Growth Rate (YoY) -33.6%
Total Assets CN¥3.43 Billion
Market Capitalization $544.93 Million USD

Valuation Analysis

Below Book Valuation: The market values Huaren Pharmaceutical Co Ltd's assets below their book value (0.16x), which may indicate investor concerns about asset quality or future growth.

Significant Asset Reduction: Huaren Pharmaceutical Co Ltd's assets decreased by 33.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Huaren Pharmaceutical Co Ltd (2007–2024)

The table below shows the annual total assets of Huaren Pharmaceutical Co Ltd from 2007 to 2024.

Year Total Assets Change
2024-12-31 CN¥3.43 Billion
≈ $501.64 Million
-33.64%
2023-12-31 CN¥5.17 Billion
≈ $755.90 Million
+0.06%
2022-12-31 CN¥5.16 Billion
≈ $755.44 Million
-8.49%
2021-12-31 CN¥5.64 Billion
≈ $825.53 Million
+65.17%
2020-12-31 CN¥3.42 Billion
≈ $499.80 Million
+26.02%
2019-12-31 CN¥2.71 Billion
≈ $396.60 Million
-13.97%
2018-12-31 CN¥3.15 Billion
≈ $461.00 Million
+9.12%
2017-12-31 CN¥2.89 Billion
≈ $422.47 Million
+5.95%
2016-12-31 CN¥2.72 Billion
≈ $398.74 Million
-0.87%
2015-12-31 CN¥2.75 Billion
≈ $402.23 Million
+4.85%
2014-12-31 CN¥2.62 Billion
≈ $383.62 Million
+10.76%
2013-12-31 CN¥2.37 Billion
≈ $346.35 Million
+32.60%
2012-12-31 CN¥1.78 Billion
≈ $261.19 Million
+43.08%
2011-12-31 CN¥1.25 Billion
≈ $182.55 Million
+8.31%
2010-12-31 CN¥1.15 Billion
≈ $168.54 Million
+81.15%
2009-12-31 CN¥635.78 Million
≈ $93.04 Million
+25.32%
2008-12-31 CN¥507.33 Million
≈ $74.24 Million
+40.08%
2007-12-31 CN¥362.18 Million
≈ $53.00 Million
--

About Huaren Pharmaceutical Co Ltd

SHE:300110 China Drug Manufacturers - Specialty & Generic
Market Cap
$544.93 Million
CN¥3.72 Billion CNY
Market Cap Rank
#12080 Global
#3723 in China
Share Price
CN¥3.15
Change (1 day)
+0.00%
52-Week Range
CN¥2.87 - CN¥3.70
All Time High
CN¥13.46
About

Huaren Pharmaceutical Co., Ltd. produces and sells non-PVC soft bag infusions in China. It offers doxofylline, levofloxacin hydrochloride, compound potassium hydrogen phosphate, and caffeine citrate, sodium chloride, glucose, glucose sodium potassium, chloride, compound sodium chloride, sodium lactate ringer, compound electrolyte, and sterilized water injections. The company also provides therape… Read more